VRDN
NASDAQ · Biotechnology
Viridian Therapeutics Inc
$23.59
+1.08 (+4.80%)
Analyst Consensus
Strong Buy
23
Analysts
High
Coverage
Price Target
Analyst Price Target
+170.6% upside
Low Target
$43.31
Average Target
$63.84
High Target
$68.31
Current Price
$23.59
Current
$23.59
$23.59
Target
$63.84
$63.84
$43.31
$63.84 avg
$68.31
Scenario Analysis
Bear Case
$43.31
83.6%
Low target
Base Case
$63.84
+170.6%
Avg target
Bull Case
$68.31
+189.6%
High target
Risk/Reward
2.3x
Favorable
Price in Context
52-Week High
$34.29
-31.2% from high
52-Week Low
$13.18
+79.0% from low
50-Day SMA
$31.51
-25.1% vs SMA
200-Day SMA
$22.43
+5.2% vs SMA
RSI (14)
17.6
Oversold
Target vs 52W High
$63.84
+86.2% vs high
Next Earnings Report
Aug 12, 2026
2d
until earnings
EPS Est: $-1.05
Earnings in 2 days. Analyst targets may shift significantly after the report.
Peer Consensus — Biotechnology
| Stock | Consensus | Analysts | Buy % | Target | Upside |
|---|---|---|---|---|---|
| ABBV | Strong Buy | 38 | 82% | $257.58 | +4.7% |
| AMGN | Hold | 43 | 49% | $190.87 | -53.6% |
| GILD | Strong Buy | 37 | 81% | $362.68 | +172.3% |
| VRTX | Strong Buy | 37 | 81% | $438.34 | -11.6% |
| REGN | Buy | 37 | 70% | $76.80 | -90.2% |
| NTRA | Strong Buy | 30 | 87% | $142.91 | -55.6% |
| RVMD | Strong Buy | 28 | 93% | $114.11 | -44.4% |
| BIIB | Buy | 43 | 67% | $91.45 | -56.0% |